Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

72.00 

-6.50 -8.3%

as of Oct 06 '22

52 Week Range:

19.40 86.50


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) -5.73
-3.11
-1.73
1.26
2.31
6.27
6.49
growth rate 0.0% 0.0% 100.0% 83.3% 171.4% 3.5%
Earnings BIT 39.42
42.53
50.20
51.85
64.49
51.66
16.90
3.81
growth rate 7.9% 18.0% 3.3% 24.4% -19.9% -67.3% -77.5%
Avg.PE 510.00
20.26
3.76
3.76
3.76
3.76
growth rate -96.0% -81.4% 0.0% 0.0% 0.0%
ROA -12.94
-21.01
-1.39
-5.99
10.74
38.57
9.84
7.49
-2.11
-8.22
growth rate 0.0% 0.0% 0.0% 100.0% 259.1% -74.5% -23.9% -100.0% 0.0%
ROE 85.94
34.12
-4.29
-14.57
growth rate -60.3% -100.0% 0.0%
ROIC 17.41
12.72
-1.29
-9.21
growth rate -26.9% -100.0% 0.0%
Cur. Ratio 1.72
1.42
1.67
2.52
2.53
3.16
3.70
2.62
2.29
2.61
growth rate -17.4% 17.6% 50.9% 0.4% 24.9% 17.1% -29.2% -12.6% 14.0%
Quick Ratio 1.35
1.04
1.27
1.84
2.01
2.49
2.98
2.06
1.66
2.08
growth rate -23.0% 22.1% 44.9% 9.2% 23.9% 19.7% -30.9% -19.4% 25.3%
Leverage 16.48
6.19
3.54
1.69
1.86
growth rate -62.4% -42.8% -52.3% 10.1%
Balance Sheet Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 41.54
37.29
36.82
40.26
43.75
43.53
54.00
89.34
growth rate -10.2% -1.3% 9.4% 8.7% -0.5% 24.1% 65.4%
Acct.Payable 15.67
11.66
18.94
17.46
17.96
18.61
16.28
20.79
growth rate -25.6% 62.5% -7.8% 2.8% 3.6% -12.5% 27.7%
Cur.Assets 81.24
90.01
110.82
147.85
195.42
172.91
184.23
235.79
growth rate 10.8% 23.1% 33.4% 32.2% -11.5% 6.5% 28.0%
Total Assets 243.15
242.38
255.90
383.86
439.83
405.92
869.82
863.78
growth rate -0.3% 5.6% 50.0% 14.6% -7.7% 114.3% -0.7%
Cash 19.74
28.60
51.18
76.29
113.40
92.92
79.61
98.51
growth rate 44.9% 79.0% 49.1% 48.6% -18.1% -14.3% 23.7%
Inventory 15.58
15.62
17.64
26.08
33.02
29.18
35.74
35.13
growth rate 0.3% 12.9% 47.9% 26.6% -11.6% 22.5% -1.7%
Cur.Liabilities 48.53
35.52
43.84
46.75
52.76
66.11
80.50
90.50
growth rate -26.8% 23.4% 6.6% 12.8% 25.3% 21.8% 12.4%
Liabilities 482.42
427.67
362.41
360.57
368.83
291.32
355.62
399.35
growth rate -11.4% -15.3% -0.5% 2.3% -21.0% 22.1% 12.3%
LT Debt 392.86
349.86
274.46
265.39
263.71
183.74
197.45
162.82
growth rate -11.0% -21.6% -3.3% -0.6% -30.3% 7.5% -17.5%
Equity -239.27
-185.29
-106.52
23.29
71.00
114.60
514.21
464.44
growth rate 0.0% 0.0% 100.0% 204.9% 61.4% 348.7% -9.7%
Common Shares 18.00
18.00
18.00
18.00
24.00
33.00
39.00
0.39
0.39
0.67
0.68
growth rate 0.0% 0.0% 0.0% 33.3% 37.5% 18.2% -99.0% 2.1% 70.2% 1.2%
Cash Flow Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 8.14
13.15
7.40
17.54
20.13
22.06
12.47
12.14
growth rate 61.6% -43.8% 137.1% 14.8% 9.6% -43.5% -2.7%
Cash From OA 11.59
21.76
49.64
54.78
61.19
80.38
16.40
53.92
growth rate 87.8% 128.1% 10.3% 11.7% 31.4% -79.6% 228.8%
FCF per Share -0.26
1.21
0.88
0.85
1.13
0.26
0.38
growth rate 100.0% -27.3% -3.4% 32.9% -77.0% 46.2%
Sale Purchase of Stock 0.01
73.54
51.13
growth rate 565,584.6% -30.5%
FCF 16.00
-8.00
-21.00
3.00
9.00
42.00
37.00
41.00
58.00
4.00
42.00
growth rate -100.0% 0.0% 100.0% 200.0% 366.7% -11.9% 10.8% 41.5% -93.1% 950.0%
Income Statement Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 301.60
293.46
301.85
331.38
343.37
347.34
339.41
425.21
growth rate -2.7% 2.9% 9.8% 3.6% 1.2% -2.3% 25.3%
Op.Income 39.42
42.53
50.20
51.85
64.49
51.66
16.90
3.81
growth rate 7.9% 18.0% 3.3% 24.4% -19.9% -67.3% -77.5%
IBT -2.37
-11.78
28.29
39.64
49.55
28.63
-11.48
-75.04
growth rate 0.0% 100.0% 40.1% 25.0% -42.2% -100.0% 0.0%
Net Income -3.56
-14.75
26.76
123.39
40.52
31.67
-13.47
-71.28
growth rate 0.0% 100.0% 361.1% -67.2% -21.8% -100.0% 0.0%
EPS -7.61
-2.32
-3.40
-0.20
-0.60
0.82
3.17
1.03
0.79
-0.25
-1.06
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 286.6% -67.5% -23.3% -100.0% 0.0%
Gross Profit 125.52
135.52
137.78
162.14
174.89
174.81
146.06
187.70
growth rate 8.0% 1.7% 17.7% 7.9% 0.0% -16.5% 28.5%
R&D 13.67
14.36
12.20
18.13
17.07
20.02
30.09
44.97
growth rate 5.0% -15.0% 48.5% -5.8% 17.3% 50.3% 49.5%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 0.36
-26.78
-4.79
4.02
58.93
growth rate -100.0% 0.0% 100.0% 1,365.1%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 58.99
54.89
64.05
89.34
172.28
growth rate -7.0% 16.7% 39.5% 92.9%
Acct.Payable 19.10
21.47
20.51
20.79
22.38
growth rate 12.4% -4.5% 1.4% 7.7%
Cur.Assets 168.35
186.21
201.52
235.79
324.75
growth rate 10.6% 8.2% 17.0% 37.7%
Total Assets 843.45
857.80
847.82
863.78
933.17
growth rate 1.7% -1.2% 1.9% 8.0%
Cash 68.86
91.50
91.48
98.51
105.36
growth rate 32.9% 0.0% 7.7% 7.0%
Inventory 30.36
31.72
33.95
35.13
34.25
growth rate 4.5% 7.0% 3.5% -2.5%
Cur.Liabilities 64.59
73.83
76.90
90.50
177.66
growth rate 14.3% 4.2% 17.7% 96.3%
Liabilities 315.33
349.66
348.47
399.35
417.32
growth rate 10.9% -0.3% 14.6% 4.5%
LT Debt 171.04
168.51
166.48
162.82
159.17
growth rate -1.5% -1.2% -2.2% -2.3%
Equity 528.12
508.14
499.34
464.44
515.85
growth rate -3.8% -1.7% -7.0% 11.1%
Common Shares 0.67
0.68
0.68
0.68
0.69
growth rate 0.3% 0.2% 0.0% 1.3%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Capital Expenditures 2.52
2.66
2.42
4.54
3.19
growth rate 5.4% -8.9% 87.8% -29.8%
Cash From OA 9.82
25.87
4.34
13.89
10.26
growth rate 163.5% -83.2% 220.0% -26.1%
Sale Purchase of Stock
growth rate
FCF 7.30
23.21
1.92
9.35
7.07
growth rate 218.1% -91.7% 386.7% -24.3%
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 92.51
101.06
102.07
129.56
208.88
growth rate 9.3% 1.0% 26.9% 61.2%
Op.Income 0.36
-26.78
-4.79
4.02
58.93
growth rate -100.0% 0.0% 100.0% 1,365.1%
IBT 14.34
-28.54
-19.84
-41.01
57.90
growth rate -100.0% 0.0% 0.0% 100.0%
Net Income 9.01
-26.66
-13.42
-40.22
42.96
growth rate -100.0% 0.0% 0.0% 100.0%
Gross Profit 41.03
46.09
42.67
57.91
129.07
growth rate 12.3% -7.4% 35.7% 122.9%
R&D 10.36
12.06
11.25
11.29
12.20
growth rate 16.4% -6.7% 0.4% 8.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (30.84)

YOY Growth Grade:

E (29.44)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 3.76 -347.83 75.27
EPS / Growth 24.2% -0.21 37.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 24.2% 37.3% 48.7%
Future PE 3.76 51.22 58.83
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.